Jo Dong Hyun, Kim Jin Hyoung, Cho Chang Sik, Cho Young-Lai, Jun Hyoung Oh, Yu Young Suk, Min Jeong-Ki, Kim Jeong Hun
Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. Tumor Microenvironment Research Center, Global Core Research Center, Seoul National University, Seoul, Republic of Korea. Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea.
Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. Tumor Microenvironment Research Center, Global Core Research Center, Seoul National University, Seoul, Republic of Korea.
Oncotarget. 2014 Nov 30;5(22):11513-25. doi: 10.18632/oncotarget.2546.
Retinoblastoma, the most common intraocular malignant tumor in children, is characterized by the loss of both functional alleles of RB1 gene, which however alone cannot maintain malignant characteristics of retinoblastoma cells. Nevertheless, the investigation of other molecular aberrations such as matrix metalloproteinases (MMPs) and miRNAs is still lacking. In this study, we demonstrate that STAT3 is activated in retinoblastoma cells, Ki67-positive areas of in vivo orthotopic tumors in BALB/c nude mice, and human retinoblastoma tissues of the advanced stage. Furthermore, target genes of STAT3 including BCL2, BCL2L1, BIRC5, and MMP9 are up-regulated in retinoblastoma cells compared to other retinal constituent cells. Interestingly, STAT3 inhibition by targeted siRNA suppresses the proliferation of retinoblastoma cells and the formation of in vivo orthotopic tumors. In line with these results, STAT3 siRNA effectively induces down-regulation of target genes of STAT3. In addition, miRNA microarray analysis and further real-time PCR experiments with STAT3 siRNA treatment show that STAT3 activation is related to the up-regulation of miR-17-92 clusters in retinoblastoma cells via positive feedback loop between them. In conclusion, we suggest that STAT3 inhibition could be a potential therapeutic approach in retinoblastoma through the suppression of tumor proliferation.
视网膜母细胞瘤是儿童最常见的眼内恶性肿瘤,其特征是RB1基因的两个功能等位基因均缺失,然而仅这一点并不能维持视网膜母细胞瘤细胞的恶性特征。尽管如此,对其他分子异常,如基质金属蛋白酶(MMPs)和微小RNA(miRNAs)的研究仍很缺乏。在本研究中,我们证明信号转导和转录激活因子3(STAT3)在视网膜母细胞瘤细胞、BALB/c裸鼠体内原位肿瘤的Ki67阳性区域以及晚期人类视网膜母细胞瘤组织中被激活。此外,与其他视网膜组成细胞相比,STAT3的靶基因包括BCL2、BCL2L1、BIRC5和MMP9在视网膜母细胞瘤细胞中上调。有趣的是,靶向小干扰RNA(siRNA)抑制STAT3可抑制视网膜母细胞瘤细胞的增殖以及体内原位肿瘤的形成。与这些结果一致,STAT3 siRNA有效诱导STAT3靶基因的下调。此外,miRNA微阵列分析以及STAT3 siRNA处理后的进一步实时聚合酶链反应(PCR)实验表明,STAT3激活与视网膜母细胞瘤细胞中miR-17-92簇的上调通过它们之间的正反馈环相关。总之,我们认为抑制STAT3可能是一种通过抑制肿瘤增殖来治疗视网膜母细胞瘤的潜在方法。